Delcath Systems, Inc. (DCTH)
Automate Your Wheel Strategy on DCTH
With Tiblio's Option Bot, you can configure your own wheel strategy including DCTH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DCTH
- Rev/Share 1.5071
- Book/Share 2.3159
- PB 7.3664
- Debt/Equity 0.0127
- CurrentRatio 15.954
- ROIC -0.0184
- MktCap 594134972.0
- FreeCF/Share -0.2188
- PFCF -78.3819
- PE -41.6024
- Debt/Assets 0.0116
- DivYield 0
- ROE -0.3513
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Wall Street Analysts Predict a 48.69% Upside in Delcath Systems (DCTH): Here's What You Should Know
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 48.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Here's Why Momentum in Delcath Systems (DCTH) Should Keep going
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Delcath Systems, Inc. (NASDAQ:DCTH ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel – CEO Sandra Pennell - SVP, Finance Vojislav Vukovic - Chief Medical Officer Kevin Muir - General Manager, Interventional Oncology Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Swayampakula Ramakanth - H.C. Wainwright Marie Thibault - BTIG Sudan Loganathan - Stephens Bill Maughan - Clear Street Yale Jen - Laidlaw & Company Operator Good day and welcome to the Delcath Systems' First Quarter 2025 Earnings Call.
Read More
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.
Read More
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in th.
Read More
Hospitals Experience FOMO In Adopting Delcath's PHP Treatment
Published: April 02, 2025 by: Seeking Alpha
Sentiment: Negative
Delcath Systemsbeat Q4 sales estimates. This was driven by increased adoption of HEPZATO KIT. However, the stock fell due to the Biotech/Medtech bear market. Delcath reported its first profitable quarter with adjusted EBITDA of $4.6 million. It has a strong cash position which will be used for its two Phase 2 trials. European expansion faces reimbursement challenges, but growing usage & the CHOPIN trial could turn the tide.
Read More
Wall Street Analysts See a 58.49% Upside in Delcath Systems (DCTH): Can the Stock Really Move This High?
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 58.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Delcath Systems, Inc. (NASDAQ:DCTH ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Sudan Loganathan - Stephens Bill Maurer - ClearStreet Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Delcath Systems' Fourth Quarter 2024 …
Read More
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of metastatic uveal melanoma (mUM). Our proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System.
Read More
About Delcath Systems, Inc. (DCTH)
- IPO Date 2018-05-03
- Website https://www.delcath.com
- Industry Medical - Specialties
- CEO Mr. Gerard J. Michel MBA, MS
- Employees 96